

MicroVascular Tissues, Inc., mVASC® Microvascular Tissue Allograft Covered by Anthem and Amerigroup

Effective 12/28/2022, Anthem Blue Cross Blue Shield and Amerigroup added coverage of mVASC® Microvascular Tissue allograft for the treatment of diabetic foot ulcers.

mVASC is a sterile, off-the-shelf, human tissue allograft consisting of microvascular (arterioles, capillaries, and venules) extracellular matrix, that restores blood flow. mVASC treatment of diabetic foot ulcers (DFUs) results in faster wound healing and improved peripheral neuropathy

Coverage is available for diabetic foot ulcers that have not healed with standard conservative therapy (such as surgical debridement, complete off-loading, and standard dressings changes) attempted for at least 1 month but not greater than 52 weeks.

The coverage decision is based on MVT's "well-designed and conducted" HIFLO Trial, where mVASC "demonstrated significant benefits of the use of this product vs. standard care in the treatment of DFUs."

See Anthem/Amerigroup Medical Policy SURG.00011 "Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting."

For additional information on mVASC coverage, please contact Microvascular Tissues, Inc.

6199 Cornerstone East, Suite 109
San Diego, CA 92121 USA
Customer Service: +1 858-522-0663
info@mvtissues.com

www.mvtissues.com